{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:01Z","timestamp":1772165701371,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Project of Jiangxi Provincial Nature Science Foundation","award":["20224ACB206008"],"award-info":[{"award-number":["20224ACB206008"]}]},{"name":"\u201cThousand Talents Plan\u201d project of introducing and training high-level talents of innovation and entrepreneurship in Jiangxi Province","award":["JXSQ2023201030"],"award-info":[{"award-number":["JXSQ2023201030"]}]},{"name":"Jiangxi Province Key Laboratory of Molecular Medicine","award":["2024SSY06231"],"award-info":[{"award-number":["2024SSY06231"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04509-1","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:06:20Z","timestamp":1760522780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections"],"prefix":"10.1186","volume":"26","author":[{"given":"Ran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"4509_CR1","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.","journal-title":"Nat Rev Dis Primers"},{"key":"4509_CR2","doi-asserted-by":"crossref","unstructured":"Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, Lv J, Zhang H. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transplant. 2024.","DOI":"10.1093\/ndt\/gfae252"},{"issue":"6","key":"4509_CR3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","volume":"6","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Mani K, Swamy A, Barwad A, Singh G, Bhowmik D, Agarwal SK. Supportive management of IgA nephropathy with Renin-Angiotensin Blockade, the AIIMS primary IgA nephropathy cohort (APPROACH) study. Kidney Int Rep. 2021;6(6):1661\u20138.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"4509_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, et al. Effect of oral Methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"5","key":"4509_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","volume":"43","author":"L Gesualdo","year":"2021","unstructured":"Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43(5):657\u201368.","journal-title":"Semin Immunopathol"},{"issue":"10084","key":"4509_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, et al. Targeted-release Budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"7","key":"4509_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11255-017-1574-2","volume":"49","author":"R Gao","year":"2017","unstructured":"Gao R, Wu W, Wen Y, Li X. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. Int Urol Nephrol. 2017;49(7):1233\u201341.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"4509_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000487330","volume":"47","author":"YZ Yang","year":"2018","unstructured":"Yang YZ, Liu LJ, Shi SF, Wang JW, Chen YQ, Lv JC, Zhang H. Effects of hydroxychloroquine on proteinuria in Immunoglobulin A nephropathy. Am J Nephrol. 2018;47(3):145\u201352.","journal-title":"Am J Nephrol"},{"issue":"1","key":"4509_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: A randomized controlled trial. Am J Kidney Dis. 2019;74(1):15\u201322.","journal-title":"Am J Kidney Dis"},{"issue":"4s","key":"4509_CR10","first-page":"S1","volume":"100","author":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"2","key":"4509_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.semarthrit.2013.01.001","volume":"43","author":"NJ Olsen","year":"2013","unstructured":"Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264\u201372.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"4509_CR12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435\u201355.","journal-title":"Autophagy"},{"issue":"11","key":"4509_CR13","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","volume":"95","author":"FD Goldman","year":"2000","unstructured":"Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its Immunomodulatory properties. Blood. 2000;95(11):3460\u20136.","journal-title":"Blood"},{"issue":"3","key":"4509_CR14","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R155.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4509_CR15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","volume":"68","author":"JC Silva","year":"2013","unstructured":"Silva JC, Mariz HA, Rocha LF Jr., Oliveira PS, Dantas AT, Duarte AL, Pitta Ida R, Galdino SL, Pitta MG. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clin (Sao Paulo). 2013;68(6):766\u201371.","journal-title":"Clin (Sao Paulo)"},{"issue":"1","key":"4509_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000484955","volume":"44","author":"N An","year":"2017","unstructured":"An N, Chen Y, Wang C, Yang C, Wu ZH, Xue J, Ye L, Wang S, Liu HF, Pan Q. Chloroquine autophagic Inhibition rebalances Th17\/Treg-Mediated immunity and ameliorates systemic lupus erythematosus. Cell Physiol Biochem. 2017;44(1):412\u201322.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"4509_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","volume":"33","author":"SC Yeo","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33(5):763\u201377.","journal-title":"Pediatr Nephrol"},{"key":"4509_CR18","doi-asserted-by":"crossref","unstructured":"Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2024.","DOI":"10.1038\/s41581-024-00885-3"},{"issue":"2","key":"4509_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","volume":"97","author":"Y Makita","year":"2020","unstructured":"Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340\u20139.","journal-title":"Kidney Int"},{"issue":"8","key":"4509_CR20","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR Inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794\u2013804.","journal-title":"J Immunol"},{"issue":"3","key":"4509_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"4509_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","volume":"76","author":"N M\u00fcller-Calleja","year":"2017","unstructured":"M\u00fcller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ. Hydroxychloroquine inhibits Proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis. 2017;76(5):891\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4509_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","volume":"45","author":"CH Jang","year":"2006","unstructured":"Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes. Rheumatology (Oxford). 2006;45(6):703\u201310.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4509_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1620\/tjem.240.199","volume":"240","author":"A Saito","year":"2016","unstructured":"Saito A, Komatsuda A, Kaga H, Sato R, Togashi M, Okuyama S, Wakui H, Takahashi N. Different expression patterns of Toll-Like receptor mRNAs in blood mononuclear cells of IgA nephropathy and IgA vasculitis with nephritis. Tohoku J Exp Med. 2016;240(3):199\u2013208.","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"4509_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2016050496","volume":"28","author":"M Muto","year":"2017","unstructured":"Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, Righini C, Maiguma M, Izui S, Tomino Y, et al. Toll-Like receptor 9 stimulation induces aberrant expression of a Proliferation-Inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol. 2017;28(4):1227\u201338.","journal-title":"J Am Soc Nephrol"},{"key":"4509_CR26","unstructured":"KDIGO. Clinical practice guideline for the management of immunoglobulin a nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV) public review draft. 2024."},{"issue":"4","key":"4509_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107(4):640\u201351.","journal-title":"Kidney Int"},{"issue":"4","key":"4509_CR28","doi-asserted-by":"publisher","first-page":"e00006","DOI":"10.1097\/IMNA-D-23-00006","volume":"10","author":"L Sheng","year":"2023","unstructured":"Sheng L, Zhang Q, Zhang X, Guo X, Wang L, Chen Y. Professor Yiping chen\u2019s experience in treating IgA nephropathy. Integr Med Nephrol Androl. 2023;10(4):e00006.","journal-title":"Integr Med Nephrol Androl"},{"key":"4509_CR29","doi-asserted-by":"publisher","first-page":"1496967","DOI":"10.3389\/fphar.2025.1496967","volume":"16","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li X, Zou H, Li M, Wang L, Luo K, Yan W, Li Y, Zhou B, Kang W, et al. Efficacy and safety of Kunxian in IgA nephropathy. Front Pharmacol. 2025;16:1496967.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4509_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: A rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4509_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000520039","volume":"2","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhang Y, Zhang H. IgA nephropathy: A Chinese perspective. Glomerular Dis. 2022;2(1):30\u201341.","journal-title":"Glomerular Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04509-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:06:23Z","timestamp":1760522783000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04509-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4509"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04509-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6711409\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University and all participants provided written informed consent before enrolling in the study, conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"566"}}